14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AURA vs DSGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Aura Biosciences, Inc. (AURA) on higher Unified Composite conviction (49.9/100 HOLD vs. 31.1/100 SELL) after splitting the core matrix 3–2 (led by Profitability & Quality), while AURA wins 2–1 across the 6-pillar growth and valuation breakdown. AURA trades at $7.21 (N/M Forward P/E, 0.0% operating margin) versus DSGN at $9.94 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. AURA 31.1/100 SELL) and 1.32β · 61% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs DSGN. Trailing 12-month operating profitability (AURA 0.0% vs DSGN 0.0%) and valuation multiples (AURA N/M vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AURA vs DSGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Aura Biosciences, Inc. (AURA) on higher Unified Composite conviction (49.9/100 HOLD vs. 31.1/100 SELL) after splitting the core matrix 3–2 (led by Profitability & Quality), while AURA wins 2–1 across the 6-pillar growth and valuation breakdown. AURA trades at $7.21 (N/M Forward P/E, 0.0% operating margin) versus DSGN at $9.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. AURA 31.1/100 SELL) and 1.32β · 61% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.3); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AURA and DSGN split Growth & Scale metrics: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $33,000 for DSGN. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.
AURA and DSGN trade at balanced relative valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus DSGN (-36.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.